March 12, 2014 12:30 ET | SOURCE: Regen BioPharma, Inc.

Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I™ IND for Treatment of Drug Resistant Aplastic Anemia